Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Semin Arthritis Rheum. 2014 Oct 22;44(5):592–596. doi: 10.1016/j.semarthrit.2014.10.008

Table 2.

Regression analysis of covariate effects on change in uric acid in insulin initiators

Model β 95% CI P value
A Crude Model: Insulin + UA1 1.29 0.15, 2.44 0.03
B Model A + age + Length of time between UA1 & UA2 1.25 0.16, 2.34 0.03
C Model B + HbA1c 1.47 −0.06, 3.00 0.06
D Model C + Creatinine + BMI 1.33 −0.28, 2.94 0.1
E Insulin+UA1+Length of time between UA1 & UA2 1.25 0.18, 2.33 0.02
Medication Use β 95% CI P value
F Model D + Allopurinol 1.36 −0.12, 2.84 0.07
G Model D + Hydrochlorothiazide 1.41 −0.17, 2.99 0.08
H Model D + Losartan 1.45 −0.07, 2.96 0.06
I Model D + Tacrolimus 1.48 −0.04, 3.00 0.06
J Model D + Cyclosporine 1.61 0.03, 3.20 0.05

β= beta co-efficient, covariate effect on change in uric acid; 95% CI=95% confidence interval; HbA1c= Hemoglobin A1C; BMI= body mass index; UA1=first uric acid measurement; UA2= second uric acid measurement.